ORIGINAL PAPER
Long-COVID symptoms after multisystem inflammatory syndrome in children during different pandemic waves
 
More details
Hide details
1
Department of Paediatrics, Jagiellonian University Medical College, Kraków, Poland
 
2
University Children’s Hospital, Department of Paediatrics, Kraków, Poland
 
3
Regional Center for Blood Donation and Blood Treatment, Kraków, Poland
 
 
Submission date: 2024-05-14
 
 
Final revision date: 2024-07-12
 
 
Acceptance date: 2024-07-29
 
 
Publication date: 2024-10-14
 
 
Corresponding author
Katarzyna Ptak
Department of Paediatrics, Jagiellonian University Medical College, Kraków, Poland
 
 
Pediatr Pol 2024;99(4):283-290
 
KEYWORDS
TOPICS
ABSTRACT
Introduction::
This study aimed to assess and compare the long-term non-cardiac complications of the multisystem inflammatory syndrome in children (MIS-C) triggered by consecutive variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Material and methods::
Multisystem inflammatory syndrome in paediatric patients was assessed in the paediatric office at 4–12 and 12–24 weeks and then by a telephone survey at least 24 weeks after hospitalisation. During each follow-up, we obtained information regarding the prevalence of long-COVID symptoms, body mass index, COVID status, need for rehospitalisations, and any consultations with specialists. Additionally, we assessed the participant’s quality of life (QoL) using the KIDSCREEN-10 questionnaire over the phone.

Results::
A total of 116 patients with MIS-C (74 during Original/Alpha, 27 during Delta, and 15 during Omicron variant surges) admitted to the Children’s Hospital of Krakow between 1 November 2020 – 5 May 2023 were included in the analysis. Regardless of the follow-up period, the frequency and variation of most symptoms did not differ significantly between groups. The only difference was a higher frequency of fatiguability/weakness in the Original/Alpha group, during the 4–12-week follow-up (37.9% vs. 10.5% vs. 9.1%; p = 0.03). The multivariable regression revealed older age (OR = 1.13, 95% CI: 1.01–1.26, p = 0.03), but not the particular variant, as an independent factor for long-COVID. Additionally, the results of long-term follow-up (more than 24 weeks) showed above-average KIDSCREEN-10 scores despite a high incidence of long-COVID symptoms.

Conclusions::
The impact of individual SARS-CoV-2 variants appears to be less important on the onset of long-COVID symptoms than other factors, such as age. Long-term follow-up indicated an overdiagnosis of non-specific long-COVID symptoms, in the case that the QoL after MIS-C was non-inferior to the general paediatric population.
REFERENCES (31)
1.
Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395: 1607. DOI: 10.1016/S0140-6736(20)31094-1.
 
2.
Belay ED, Abrams J, Oster ME, et al. Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic. JAMA Pediatr 2021; 175: 837-845.
 
3.
Ludwikowska KM, Okarska-Napierała M, Dudek N, et al. Distinct characteristics of multisystem inflammatory syndrome in children in Poland. Sci Rep 2021; 11: 23562. DOI: 10.1038/s41598-021-02669-2.
 
4.
Pino R, Antoñanzas JM, Paredes-Carmona F, et al. Multisystem inflammatory syndrome in children and SARS-CoV-2 variants: a two-year ambispective multicentric cohort study in Catalonia, Spain. Eur J Pediatr 2023; 182: 1897-1909.
 
5.
Otten MH, Buysse CMP, Buddingh EP, et al. Neurocognitive, psychosocial, and quality of life outcomes after multisystem inflammatory syndrome in children admitted to the PICU. Pediatric Critical Care Medicine 2023; 24: 289-300.
 
6.
Constantin T, Pék T, Horváth Z, et al. Multisystem inflammatory syndrome in children (MIS-C): implications for long COVID. Inflammopharmacology 2023; 31: 2221-2236.
 
7.
Penner J, Abdel-Mannan O, Grant K, et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study. Lancet Child Adolesc Health 2021; 5: 473-482.
 
8.
Stopyra L, Kowalik A, Stala J, et al. Characteristics of hospitalized pediatric patients in the first five waves of the COVID-19 pandemic in a single center in Poland – 1407 cases. J Clin Med 2022; 11: 6806. DOI: 10.3390/jcm11226806.
 
9.
Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2. Arthritis Rheumatol 2021; 73: e13-e29. DOI: 10.1002/art.41616.
 
10.
Standards. Available from: https://www.who.int/tools/chil... (Accessed: 09.01.2024).
 
11.
CoVariants. Available from: https://covariants.org/ (Accessed: 29.01.2024).
 
12.
Long COVID or post-COVID conditions | CDC. Available from: https://www.cdc.gov/coronaviru... (Accessed: 30.12.2023).
 
13.
Welcome to our KIDSCREEN website – kidscreen.org. Available from: https://www.kidscreen.org/engl... (Accessed: 10.12.2023).
 
14.
Noval Rivas M, Porritt RA, Cheng MH, et al. Multisystem inflammatory syndrome in children and long COVID: the SARS-CoV-2 viral superantigen hypothesis. Front Immunol 2022; 13: 941009. DOI: 10.3389/fimmu.2022.941009.
 
15.
Roge I, Kivite-Urtane A, Smane L, et al. Short- and mid-term outcomes of multisystem inflammatory syndrome in children: a longitudinal prospective single-center cohort study. Front Pediatr 2023; 11: 1223266. DOI: 10.3389/fped.2023.1223266.
 
16.
Zheng YB, Zeng N, Yuan K, et al. Prevalence and risk factor for long COVID in children and adolescents: a meta-analysis and systematic review. J Infect Public Health 2023; 16: 660-672.
 
17.
Zimmermann P, Pittet LF, Curtis N. Long covid in children and adolescents. BMJ 2022; 376: o143. DOI: 10.1136/bmj.o143.
 
18.
Osmanov IM, Spiridonova E, Bobkova P, et al. Risk factors for long covid in previously hospitalised children using the ISARIC global follow-up protocol: a prospective cohort study. Eur Respir J 2022; 59: 2101341. DOI: 10.1183/13993003.01341-2021.
 
19.
Ashkenazi-Hoffnung L, Shmueli E, Ehrlich S, et al. Long COVID in children: observations from a designated pediatric clinic. Pediatr Infect Dis J 2021; 40: e509-e511. DOI: 10.1097/INF.00000000- 0000­3285.
 
20.
Ravens-Sieberer U, Erhart M, Devine J, et al. Child and adolescent mental health during the COVID-19 pandemic: results of the three-wave longitudinal COPSY study. J Adolesc Health 2022; 71: 570-578.
 
21.
Vallejo-Slocker L, Fresneda J, Vallejo MA. Psychological wellbeing of vulnerable children during the COVID-19 pandemic. Psicothema 2020; 32: 501-507.
 
22.
Seyfi S, Alijanpour R, Aryanian Z, et al. Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity. J Med Life 2022; 15: 631-634.
 
23.
Czech T, Sugihara S, Nishimura Y. Characteristics of hair loss after COVID‐19: a systematic scoping review. J Cosmet Dermatol 2022; 21: 3655-3662.
 
24.
Fernández-de-las-Peñas C, Notarte KI, Peligro PJ, et al. Long-COVID symptoms in individuals infected with different SARS-CoV-2 variants of concern: a systematic review of the literature. Viruses 2022; 14: 2629. DOI: 10.3390/v14122629.
 
25.
Rollins CK, Calderon J, Wypij D, et al. Neurological and psychological sequelae associated with multisystem inflammatory syndrome in children. JAMA Netw Open 2023; 6: e2324369. DOI: 10.1001/jamanetworkopen.2023.24369.
 
26.
Manning JC, Pinto NP, Rennick JE, et al. Conceptualizing post intensive care syndrome in children – the PICS-p framework. Pediatr Crit Care Med 2018; 19: 298-300.
 
27.
Son MBF, Murray N, Friedman K, et al. Multisystem inflammatory syndrome in children – initial therapy and outcomes. N Engl J Med 2021; 385: 23-34.
 
28.
Minoia F, Lucioni F, Heshin-Bekenstein M, et al. Approaches to SARS-CoV-2 and other vaccinations in children with a history of multisystem inflammatory syndrome (MIS-C): an international survey. Front Pediatr 2022; 10: 1030083. DOI: 10.3389/fped.2022. 1030083.
 
29.
Buddingh EP, Vossen ACTM, Lamb HJ, et al. Reinfection with severe acute respiratory syndrome coronavirus 2 without recurrence of multisystem inflammatory syndrome in children. Pediatr Infect Dis J 2021; 40: e491-e492. DOI: 10.1097/INF.0000000000003280.
 
30.
Soysal A, Topçu B, Atıcı S, et al. MIS-C patients who were reinfected with SARS-CoV-2. Report of 2 cases. Arch Argent Pediatr 2023; 121: e202202893. DOI: 10.5546/aap.2022-02893.eng.
 
31.
Levy M, Recher M, Hubert H, et al. Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France. JAMA 2022; 327: 281-283.
 
Journals System - logo
Scroll to top